alpha-En (ALPE) 10-K 31 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2017	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	alpha-En Corp
Entity Central Index Key	1,023,298
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 25,300
Entity Common Stock, Shares Outstanding		33,282,089
Trading Symbol	ALPE
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash	$ 442	$ 730
Prepaid expenses	91	301
Restricted cash	100
Due from related party		61
Total current assets	633	1,092
Long-term deposit	50
Property and equipment, net	541	2
Total assets	1,224	1,094
Current liabilities
Accounts payable and accrued expenses	964	341
Advances from related parties	78	62
Total current liabilities	1,042	403
Total liabilities	1,042	403
COMMITMENTS AND CONTINGENCIES
Stockholders' equity:
Preferred stock par value 0.01: 2,000,000 shares authorized; none issued or outstanding
Common stock	333	322
Additional paid-in capital	13,987	10,705
Treasury stock at cost: 714,750 shares as of December 31, 2016 and December 31, 2015	(69)	(69)
Accumulated deficit	(13,749)	(10,169)
Stockholders' equity attributed to alpha-En Corporation stockholders	502	789
Non-controlling interest	(320)	(98)
Total stockholders' equity	182	691
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	1,224	1,094
Common Class B [Member]
Stockholders' equity:
Common stock

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Preferred stock, par or stated value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par or stated value per share	$ 0.01	$ 0.01
Common stock, shares authorized	35,000,000	35,000,000
Common stock, shares, issued	33,282,089	32,235,525
Common stock, shares, outstanding	33,282,089	32,235,525
Treasury stock, shares	714,750	714,750
Common Class B [Member]
Common stock, par or stated value per share
Common stock, shares authorized	1,000,000	1,000,000
Common stock, shares, issued
Common stock, shares, outstanding

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating expenses
General and administrative	$ 1,666	$ 1,040
Legal and professional fees	695	150
Research and development	1,436	651
Total operating expenses	3,797	1,841
Net loss	(3,797)	(1,841)
Less: net loss attributable to non-controlling interest	(217)	(49)
Add: Deemed dividend - issuance of common shares under anti-dilution provisions	(116)
Add: Deemed dividend - inducement to exercise warrants	(378)
Net loss attributable to alpha-En Corporation common stockholders	$ (4,074)	$ (1,792)
Net loss per share attributable to alpha-En Corporation common stockholders
Basic and diluted	$ (0.12)	$ (0.06)
Weighted average shares outstanding:
Basic and diluted	33,347,318	30,849,087

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2013	$ 267	$ 8,130	$ (69)	$ (8,377)		$ (49)
Balance, shares at Dec. 31, 2013	26,699,497		714,750
Correction to outstanding shares	$ 36	(36)
Correction to outstanding shares, Shares	3,586,028
Balance at Dec. 31, 2014	$ 303	8,094	$ (69)	(8,377)		(49)
Balance, shares at Dec. 31, 2014	30,285,525		714,750
Correction to outstanding shares, Shares
Sale of subsidiary common stock and warrants for cash		814			(49)	765
Stock based compensation (shares and options)	$ 3	978				981
Stock based compensation (shares and options), Shares	350,000
Issuance of common stock and warrants in a private placement	$ 16	819				835
Issuance of common stock and warrants in a private placement, shares	1,600,000
Issuance of subsidiary common stock for services
Deemed dividend - inducement to exercise warrants
Net loss				(1,792)	(49)	(1,841)
Balance at Dec. 31, 2015	$ 322	10,705	$ (69)	(10,169)	(98)	$ 691
Balance, shares at Dec. 31, 2015	32,235,525		714,750			32,235,525
Non-employee options exercised for cash	$ 1	10				$ 11
Non-employee options exercised for cash, shares	100,000
Warrants exercised for cash	$ 2	213				215
Warrants exercised for cash, shares	221,875
Stock based compensation (shares and options)	$ 7	1,575				1,582
Stock based compensation (shares and options), Shares	650,000
Issuance of common stock and warrants in a private placement	$ 14	1,391				1,405
Issuance of common stock and warrants in a private placement, shares	1,394,689
Shares cancellation	$ (14)	14
Shares cancellation, Shares	(1,420,000)
Shares issued due to anti-dilution	$ 1	115				116
Shares issued due to anti-dilution, Shares	100,000
Deemed dividend - anti-dilution shares issued			$ (116)			(116)
Issuance of subsidiary common stock for services		80			(5)	75
Warrants granted as inducement to exercise warrants		378				378
Deemed dividend - inducement to exercise warrants		(378)				(378)
Net loss				(3,580)	(217)	(3,797)
Balance at Dec. 31, 2016	$ 333	$ 13,987	$ (69)	$ 13,749	$ (320)	$ 182
Balance, shares at Dec. 31, 2016	33,282,089		714,750

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net loss	$ (3,797)	$ (1,841)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	12
Stock-based compensation	1,582	981
Issuance of subsidiary common stock for service	75
Changes in operating assets and liabilities of business, net of acquisitions:
Prepaid expenses	210	(296)
Due from related parties	61	(61)
Accounts payable and accrued expenses	384	322
Net cash used in operating activities	(1,473)	(895)
Cash flows from investing activities
Restricted cash	(150)
Purchase of fixed assets	(312)	(2)
Net cash used in investing activities	(462)	(2)
Cash flows from financing activities
Issuance of subsidiary common stock and warrants for cash		765
Proceeds from issuance of common stock and warrants in private placements	1,405	835
Non-employee options exercised for cash	11
Warrants exercised for cash	215
Advances from related parties	86	11
Repayments of advances from related parties	(70)	(87)
Net cash provided by financing activities	1,647	1,524
Net (decrease) increase in cash	(288)	627
Cash at beginning of period	730	103
Cash at end of period	442	730
Non cash financing and investing activities:
Issuance of restricted stock to employee	7	3
Shares cancellation	14
Deemed dividend related to issuance of warrants as inducement to exercise existing warrants	378
Deemed dividend related to issuance of common shares under anti-dilution provisions	116
Purchase of property and equipment included in accounts payable and accrued expenses	$ 239

Organization and Operations

Organization and Operations	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Operations	Note 1 - Organization and Operations alpha-En Corporation (together with its subsidiaries, the “Company”) was incorporated in Delaware on March 7, 1997 On February 25, 2009, alpha-En Corporation was granted a license for an exclusive, worldwide, transferable, perpetual license to use certain proprietary technology for the processing of lithium for use in batteries. After much effort, it was determined the process was not commercially feasible and efforts surrounding this technology were abandoned in 2011. The Company negotiated an amendment and release related to this license. (See Note 7) During the period from 2013 to the present, alpha-En Corporation has been exclusively focused on developing its own technology for the production of highly pure lithium metal, from the bench scale through multiple demonstrations, with the end goal of commercialization. During this time, alpha-En Corporation has also been pursuing strategic partnerships both commercially and with research institutions. Formation of Majority-Owned Subsidiary In September 2014, alpha-En Corporation formed Clean Lithium Corporation (“CLC”) under the laws of New York State as a wholly owned subsidiary with a nominal share capital of $100,000. Following the sale of CLC’s shares, the ownership is as follows: Stockholder Shares Percentage alpha-En Corporation 9,095,000 90.95 % Non-controlling interests 905,000 9.05 % Total: 10,000,000 100.00 %

Going Concern and Liquidity

Going Concern and Liquidity	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Liquidity	Note 2 – Going Concern and Liquidity The Company adopted Accounting Standards Update No. 2014-15, “Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”) The Company’s consolidated financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in the consolidated financial statements, the Company had an accumulated deficit of approximately $13.7 million at December 31, 2016, a net loss of approximately $3.8 million and $1.8 million and approximately $1.5 million and $895,000 net cash used in operating activities for the years ended December 31, 2016 and 2015, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is attempting to further develop the intellectual property associated with its technology; broaden its patent portfolio; scale up our production of various products; and begin generating revenue; however, the Company’s cash position is not sufficient to support its daily operations. While the Company believes in the viability of its technology and in its ability to raise additional funds by way of a public or private offering, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon its ability to raise additional funds by way of a public or private offering and its ability to further develop its technology and generate sufficient revenue. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Significant and Critical Accoun

Significant and Critical Accounting Policies and Practices	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant and Critical Accounting Policies and Practices	Note 3 - Significant and Critical Accounting Policies and Practices Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company’s consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated. Use of Estimates The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value measurements, stock-based compensation, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. Fair Value Measurement The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The carrying amounts of cash accounts payable and accrued expenses and advances from related parties approximate fair value as these accounts are largely current and short term in nature. Cash As of December 31, 2016 and 2015, substantially all of the Company’s cash was held by major financial institutions and the balance at certain times may exceed the maximum amount insured by the Federal Deposits Insurance Corporation. However, the Company has not experienced losses on these accounts and management believes that the Company is not exposed to significant risks on such accounts. Property and Equipment Lab equipment, leasehold improvements and office equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset, generally three years. Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value. Accounting for Warrants The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging (“ASC 815”). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants as of the date of each offering and reassesses such classification at each financial reporting date. The Company determined that such instruments did not meet the criteria for liability classification. Research and Development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations, consultants, the cost of acquiring and manufacturing research trial materials, and costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development Contingencies The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Stock-Based Compensation The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit. Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share excludes the potential impact of common stock options, unvested shares of restricted stock and outstanding common stock purchase warrants because their effect would be anti-dilutive. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at December 31, 2016 and 2015 are as follows: As of December 31, 2016 2015 Warrants to purchase common stock 3,271,875 1,850,000 Options to purchase common stock 4,530,000 3,870,000 Unvested restricted stock - 650,000 Total 7,801,875 6,370,000 Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests. Reclassfication Certain prior period amounts have been reclassified to conform to current year presentation. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”) . Under ASU 2016-09, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (“APIC”). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement and the APIC pools will be eliminated. In addition, ASU 2016-09 eliminates the requirement that excess tax benefits be realized before companies can recognize them. ASU 2016-09 also requires companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Furthermore, ASU 2016-09 will increase the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer’s statutory income tax withholding obligation. An employer with a statutory income tax withholding obligation will now be allowed to withhold shares with a fair value up to the amount of taxes owed using the maximum statutory tax rate in the employee’s applicable jurisdiction(s). ASU 2016-09 requires a company to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on the statement of cash flows. Under current GAAP, it was not specified how these cash flows should be classified. In addition, companies will now have to elect whether to account for forfeitures on share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. These aspects of ASU 2016-09 are effective for reporting periods beginning after December 15, 2016, with early adoption permitted provided that all of the guidance is adopted in the same period. The Company adopted the standard as of January 1, 2017 and adoption did not have a material impact on the Company’s consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4 – Property and Equipment The components of property and equipment as of December 31, 2016 and 2015, at cost are (dollars in thousands): ($ in thousands) Useful Life (Years) December 31, 2016 December 31, 2015 Lab equipment 3 173 2 Office furniture and equipment 3 12 - Leasehold improvement 368 - Gross property and equipment 553 2 Less: Accumulated depreciation (12 ) - Property and equipment, net $ 541 $ 2 The Company’s depreciation expense for the years ended December 31, 2016 and 2015 was $12,000 and $0, respectively.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Note 5 – Related Party Transactions Advances from Related Parties From time to time, stockholders of the Company advance funds to the Company for working capital purposes. Those advances are unsecured, non-interest bearing and due on demand. During the year ended December 31, 2016, the Company borrowed approximately $86,000 additional funds from related parties and made $70,000 repayments to related parties. During the year ended December 31, 2015, the Company borrowed approximately $11,000 additional funds from its related parties and made $87,000 repayments to related parties. As of December 31, 2016 and 2015, the outstanding amount of the advances from related parties was $78,000 and $62,000, respectively. Free Office Space During 2015 and through September 2016, the Company has been provided office space by its Chairman of the Board at no cost. Management determined that such cost was nominal and did not recognize the rent expense in its financial statements. Restricted Stock Grant to Chief Executive Officer and Associated Withholding Payments During the year ended December 31, 2016, Steven M. Fludder, Chief Executive Officer, paid the Company a withholding tax obligation of $198,000 related to the grant of restricted stock in 2015. Stock Sales to Current Director On June 3, 2016 the Company entered into a private placement offering with KielStrand Capital, LLC, of which Director Jim. Kilman is the CEO, under which it sold 100,000 shares of common stock and 250,000 warrants for $250,000. The warrants have a five year term and an exercise price of $3.79 per share. On November 1, 2016 the Company entered into an additional private placement offering with KielStrand Capital, LLC under which it sold 100,000 shares of common stock and 250,000 warrants for $100,000. The warrants have a 5 year term and an exercise price of $1.16 per share. In connection with the second private placement KielStrand Capital, LLC also received an additional 100,000 shares of common stock pursuant to certain anti-dilution protections provided in connection with the June 3, 2016 private placement. Subsequent to these private placements, Mr. Kilman joined our Board of Directors on November 3, 2016. On December 6, 2016, the Company cancelled 210,000 shares of common stock and exchanged 210,000 shares of common stock into options for the exercise of 210,000 shares of common stock, with an exercise price of $1.08 and a 5 year term, to a consultant who previously performed services prior to 2014. The consultant is related to George McKeegan, a Board member of the Company. The Company made payments for secretarial services to an entity affiliated with member of the Board of Directors. During the year ended December 31, 2016 payments amounted to approximately $16,000.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders' Equity	Note 6 – Stockholders’ Equity Adjustment to Outstanding Shares and Options In the consolidated financial statements for the years ended December 31, 2015 and 2014 filed with the SEC, the Company incorrectly excluded 3.6 million shares of common stock and 150,000 non-employee stock options, of which 75,000 were vested, in the calculation of basic and diluted earnings per share, weighted average and number of common shares outstanding. Given the net loss in 2014 and 2015, the excluded stock options had no impact on loss per share as their effect, if included, would have been anti-dilutive. In addition, the exclusion of 3.6 million shares of common stock also did not have a material effect on loss per share calculations. As a result, net loss per common share outstanding, basic and diluted, weighted average and the number of common shares outstanding were misstated by an amount that the Company has determined to be immaterial. The exclusion of such shares does not affect total stockholders' equity or net loss. The following table provides a comparison between the previously filed numbers and the numbers after the correction as of December, 31(in thousands, except share): Previous Filings After Correction of Error 2015 2014 2015 2014 Total shares outstanding 28,649,497 26,699,497 32,235,525 30,285,525 Common stock $ 286 $ 267 $ 322 $ 303 Additional paid-in capital $ 10,741 $ 8,130 $ 10,705 $ 8,094 The following table provides a comparison between the previously filed numbers and the numbers after the correction for the years ended December, 31: Previous Filings After Correction of Error 2015 2014 2015 2014 Net loss $ 1,792,000 $ 47,000 $ 1,792,000 $ 47,000 Net loss per share $ (0.07 ) $ (0.00 ) $ (0.06 ) $ (0.00 ) Weighted-average shares 27,263,059 26,394,554 30,849,087 29,980,582 In accordance with the SEC’s Staff Accounting Bulletin Nos. 99 (“SAB 99”), the Company evaluated this error and, based on an analysis of quantitative and qualitative factors, determined that the error was immaterial to the prior reporting periods affected. Therefore, as permitted by SAB 99, the Company corrected, in the current filing, the calculation of basic earnings per share and weighted average number of common shares outstanding as of December 31, 2015 and 2014. Common Stock During the year ended December 31, 2015 the company entered into four private placement offerings with four investors and issued 1.6 million shares of its common stock, 680,000 shares of CLC’s common stock and warrants to purchase 1.7 million shares of its common stock for $1.6 million. During the year ended December 31, 2016, the Company entered into sixteen private placement offerings with fourteen investors and issued approximately 1.5 million shares of its common stock and warrants to purchase approximately 1.4 million shares of common stock for $1.4 million. The warrants have a 5-year term and a weighted-average exercise price of $1.68. 100,000 shares issued in this offering are subject to “price protection” for a period of one year. Specifically, in the event the Company issues to any person common stock or their equivalent at a lower price per share than $2.50 (the “Lower Price”), the Company shall, simultaneously with the issuance of such shares, issue that investor a number of additional common shares (the “Additional Shares”) necessary to cause the 100,000 purchased plus the Additional Shares to have a combined average cost per share equal to the Lower Price, provided that in no event shall the Additional Shares exceed 100,000 shares. The price protection featured was analyzed by the Company and the Company determined that such feature was not required to be bifurcated from the common stock and recorded as a derivative as the price protection feature is clearly and closely related to an equity host. In November 2016 the Lower Price protection was triggered and the Company became obligated to issue an additional 100,000 shares of common stock under the arrangement. As of December 31, 2016, the Company does not have enough authorized shares for the exercise of outstanding options and warrants. The Company believes that the process required to increase the authorized shares is perfunctory and has therefore not reclassified any outstanding options or warrants from equity to liabilities. (see note 9) During the year ended December 31, 2016, the company also issued 75,000 shares of its subsidiary, CLC, to a consultant, who is also a stockholders for the service provided, and the shares were valued at $1.00 per share based upon the estimated fair value on the date the shares were issued. A related expense of $75,000 was recorded during the year ended December 31, 2016. During the year ended December 31, 2016, 221,875 warrants with a weighted average exercise price of $0.97 were exercised for cash consideration of $215,000. The investors were granted 221,875 additional warrants in August 2016 with a 5-year term and an exercise price of $2.70 per share. The warrants were accounted for as an inducement and accordingly $378,000 which reflects the fair value of the warrants was recorded as a deemed distribution. The fair value of the warrants was determined using a Black-Scholes model with the following assumptions: risk free rate – 1.14%, volatility – 78.49%, expected term – 5 years, expected dividends – N/A. As of December 31, 2016, there were warrants to purchase 3,271,875 shares of common stock issued and outstanding. Stock Options 2016 Equity Plan In the fiscal year ended December 31, 2016, the Company adopted the 2016 Equity Plan, an omnibus equity incentive plan to be administered by the Company’s Board of Directors to which the Company may issue its common shares in connection with grants of stock options to employees and consultants of the Company. The 2016 Equity Plan was approved by a subset of the Company’s stockholders, however, pursuant to applicable law, the 2016 Equity Plan will not become effective until twenty days after the mailing of an Information Statement on Schedule 14C to all of the Company’s stockholders. The Company anticipates filing such Information Statement on Schedule 14C with the Securities and Exchange Commission as soon as possible following the filing of this Form 10-K for the Fiscal year ended December 31, 2016. The grant date fair value of stock options granted to employees during the years ended December 31, 2016 and 2015 was approximately $305,000 and $135,000, respectively. The fair value of the Company’s common stock was based upon the publicly quoted price on the date that the final approval of the awards was obtained. The Company does not expect to pay dividends in the foreseeable future so therefore the expected dividend yield is 0%. The expected term for stock options granted with service conditions represents the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach prescribed by the Securities and Exchange Commission's Staff Accounting Bulletin for “plain vanilla” options. The expected term for stock options granted with performance and/or market conditions represents the estimated period estimated by management by which the performance conditions will be met. The Company obtained the risk-free interest rate from publicly available data published by the Federal Reserve. The Company uses a methodology in estimating its volatility percentage from a computation that was based on a comparison of average volatility rates of similar companies to a computation based on the standard deviation of the Company’s own underlying stock price's daily logarithmic returns. The fair value of options granted in 2016 and 2015 was estimated using the following weighted-average assumptions: As of December 31, 2016 2015 Exercise price $ 1.03 $ 0.28 Expected stock price volatility 79 % 78 % Risk-free rate of interest 1.37 % 1.28 % Term (years) 3.7 3.8 A summary of option activity under the Company’s employee stock option plan for year ended December 31, 2016 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 1,050,000 $ 0.27 $ 757,000 5.1 Employee options granted 525,000 0.97 182,000 5.7 Outstanding as of December 31, 2016 1,575,000 $ 0.50 $ 1,264,000 4.7 Options vested and expected to vest as of December 31, 2016 1,575,000 $ 0.50 $ 1,264,000 4.7 Options vested and exercisable as of December 31, 2016 687,500 $ 0.36 $ 647,000 3.8 A summary of the activity of options that the Company granted to non-employees for the year ended December 31, 2016 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 (as reported) 2,670,000 $ 0.20 $ 2,118,000 4.0 Adjustment to stock options 150,000 0.10 134,000 2.1 Outstanding as of December 31, 2015 (as adjusted) 2,820,000 $ 0.19 $ 2,252,000 3.9 Non-employee options granted 235,000 $ 1.15 $ 46,000 4.9 Non-employee options exercised (100,000 ) 0.11 119,000 - Outstanding as of December 31, 2016 2,955,000 $ 0.27 $ 3,053,000 3.2 Options vested and expected to vest as of December 31, 2016 2,955,000 $ 0.27 $ 3,053,000 3.2 Options vested and exercisable as of December 31, 2016 1,667,500 $ 0.30 $ 1,660,700 3.3 Estimated future stock-based compensation expense relating to unvested stock options is approximately $225,000 as of December 31, 2016 and will be amortized over the remaining 3.8 years. Restricted Stock On October 20, 2015, Steven M. Fludder was appointed to be the Company’s Chief Executive Officer. Jerome I. Feldman, the Company’s continuing Chairman of the Board, resigned such position in order to bring in Mr. Fludder. Pursuant to a term sheet the Company granted Mr. Fludder 350,000 shares of the Company’s common stock on December 18, 2015 and an additional 650,000 shares of common stock on January 15, 2016. There were $136,000 and $264,000 in expenses related to restricted stock awards for the years ended December 31, 2016 and 2015. A summary of the restricted stock award activity for the year ended December 31, 2016 is as follows: Number of Units Weighted Average Grant Date Fair Value Nonvested at December 31, 2015 650,000 $ 0.40 Vested (650,000 ) $ 0.40 Nonvested at December 31, 2016 - $ - A summary of the restricted stock award activity for the year ended December 31, 2015 is as follows: Number of Units Weighted Average Grant Day Fair Value Nonvested at December 31, 2014 - $ - Granted 1,000,000 $ 0.40 Vested (350,000 ) $ 0.40 Nonvested at December 31, 2015 650,000 $ 0.40 Warrants A summary of the status of the Company’s outstanding warrants as of December 31, 2016 and changes during the year then ended is presented below: Number of Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 1,850,000 $ 0.31 $ 1,249,000 4.3 Issued 1,643,750 1.82 250,000 2.3 Exercised (221,875 ) 0.97 73,000 4.2 Outstanding as of December 31, 2016 3,271,875 $ 1.02 $ 2,000,000 3.9 Warrants exercisable as of December 31, 2016 3,271,875 $ 1.02 $ 2,000,000 3.9 Stock-based Compensation Expense Stock-based compensation expense for the year ended December 31, 2016 and 2015 was comprised of the following (in thousands): For the Years Ended December 31, 2016 2015 Employee restricted stock awards $ 136 $ 264 Employee stock option awards 201 30 Non-employee option awards 1,245 687 Total compensation expense $ 1,582 $ 981

Contingencies and Commitments

Contingencies and Commitments	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Contigencies and Commitments	Note 7 – Contingencies and Commitments On March 22, 2016, the Company entered into a lease (the “Lease”) with Hudson View Building #3, LLC (“the “Landlord”), for office and laboratory space located in Yonkers, New York (the “Leased Premise”). The Leased Premise consists of approximately 8,000 square feet. The Lease has a term of 87 months from the lease commencement date, which is the date upon which the Landlord has substantially completed certain interior leasehold improvements to the Leased Premise. The annual rent of the first year of the lease is approximately $208,000, increasing by 1.5% on each anniversary of the lease commencement date. In the event of a termination of the lease following a default by the Company, the Company will be obligated to pay the sum of the rent payable for the remainder of the lease term. In connection with this lease, the Company obtained an Irrevocable Standby Letter of Credit (the “Letter of Credit”) from Cash Bank for a sum not exceeding $150,000. The Company has deposited this amount with Cash bank as collateral for the Letter of Credit and recorded the amount as restricted cash in the consolidated balance sheets as of December 31, 2016. As of December 31, 2016, the landlord had not substantially completed the certain leasehold improvements. Contractual minimal lease payments are as follows (in thousands): 2017 $ 121 2018 210 2019 213 2020 216 2021 220 Thereafter 543 Total $ 1,523 On February 25, 2009, the Company was granted an exclusive, worldwide, transferable, perpetual license to use certain proprietary technology for the processing of lithium for use in batteries and other fields. Commencing in October 2010, working through a third party, the Company conducted a series of tests to determine if the process worked and, based on the results, initially believed that the process produced lithium, however it did not prove to be commercially feasible and research and development efforts involving this license were abandoned. In exchange for the license, the Company had certain financial, share issuance and royalty obligations if certain sale thresholds were met. However, since contractually agreed thresholds were not met and the technology was not used, the Company negotiated an amendment and release which was finalized in January 2017. Pursuant to the amendment and release, the third party retained two million of the three million total shares from the original license and forfeited the remaining one million shares. The two million shares retained by the third party are subject to customary transfer restrictions for restricted shares. The Company maintains an executive office in Tarrytown, New York. This space was previously provided to the Company without charge by our Executive Chairman, Jerome I. Feldman. Beginning in September 2016 we began incurring rent for this space of approximately $5,000 per month, plus taxes and utilities to the current owner Cushman & Wakefield of Pennsylvania, Inc. The lease commenced on May 1, 2016 and terminates on April 30, 2018.

Deferred Tax Assets and Income

Deferred Tax Assets and Income Tax Provision	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Deferred Tax Assets and Income Tax Provision	Note 8 – Deferred Tax Assets and Income Tax Provision The Company had no income tax expense due to operating loss incurred for the years ended December 31, 2016 and 2015. The tax effects of temporary differences and tax losses and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2016 and 2015 are comprised of the following (dollars in thousands): As of December 31, 2016 2015 Deferred tax assets: Net-operating loss carryforward $ 1,196 $ 342 Stock based compensation 1,043 431 Total Deferred Tax Assets 2,239 773 Valuation allowance (2,239 ) (773 ) Deferred Tax Asset, Net of Allowance $ - $ - For the year ended 2016 2015 Federal Current $ - $ - Deferred 1,251 643 State Current - - Deferred 215 110 Change in Valuation Allowance (1,466 ) (753 ) Income Tax Provision (Benefit) $ - - At December 31, 2016, the Company had net operating loss carry forwards for federal and state tax purposes of approximately $3.1 million which expires beginning in 2036. The Company has not performed a detailed analysis to determine whether an ownership change under Section 382 of the IRC has occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of net operating loss carryforwards attributable to periods before the change. Any limitation may result in expiration of all, or a portion of the NOL or potential research and development credit carryforwards before utilization. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and taxing strategies in making this assessment. In case the deferred tax assets will not be realized in future periods, the Company has provided a valuation allowance for the full amount of the deferred tax assets at December 31, 2016. The valuation allowance increased by approximately $1.5 million and $753,000 for the years ended as of December 31, 2016 and 2015, respectively. The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows: For the years ended December 31, 2016 2015 Statutory Federal Income Tax Rate (34.0 )% (34.0 )% State Taxes, Net of Federal Tax Benefit (5.8 )% (5.8 )% Change in Valuation Allowance 39.8 % 39.8 % Income Taxes Provision (Benefit) 0.0 % 0.0 % The Company has not identified any uncertain tax positions requiring a reserve as of December 31, 2016. The Company is in the process of preparing historical federal and state tax returns. Therefore, the Company’s net operating loss carryovers will not be available to offset future taxable income, if any, until the tax returns are filed.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 9 – Subsequent Events On February 23, 2017, the Board of Directors of the Company appointed Nathan Wasserman to become Chief Financial Officer of the Company, effective as of March 1, 2017. Pursuant to a term sheet dated February 27, 2017, Mr. Wasserman agreed to serve as our Chief Financial Officer for an initial term of three years. We granted Mr. Wasserman stock options to purchase a total of 500,000 shares of common stock at an exercise price of $1.50 per share, of which 150,000 vested immediately, 150,000 will vest in his second year of service and 200,000 will vest in his third year of service. Mr. Wasserman will also receive a starting salary of $5,000 per month. Amended and Restated Certificate of Incorporation On March 29, 2017 the Board of Directors of the Company and a subset of the Company’s stockholders representing in excess of 75% of the Company’s currently issued and outstanding voting stock approved of the amendment and restatement of the Company’s Certificate of Incorporation (the “Restated Certificate”) to make certain corporate governance updates and to increase the authorized capital stock of the Company to 60,000,000 shares, of which 57,000,000 will be shares of Common Stock, par value $0.01 per share, 1,000,000 will be shares of Class B Common Stock, par value $0.01 per share and 2,000,000 will be shares of preferred stock, par value $0.01 per share. Pursuant to applicable law, the Restated Certificate will not become effective until twenty days after the mailing of an Information Statement to all of the Company’s stockholders and after the filing of the Restated Certificate with the Delaware Secretary of State. The Company anticipates filing such Information Statement on Schedule 14C with the Securities and Exchange Commission as soon as possible following the filing of its Form 10-K for the Fiscal year ended December 31, 2016.

Significant and Critical Acco16

Significant and Critical Accounting Policies and Practices (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company’s consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value measurements, stock-based compensation, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Fair Value Measurement	Fair Value Measurement The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The carrying amounts of cash accounts payable and accrued expenses and advances from related parties approximate fair value as these accounts are largely current and short term in nature.
Cash	Cash As of December 31, 2016 and 2015, substantially all of the Company’s cash was held by major financial institutions and the balance at certain times may exceed the maximum amount insured by the Federal Deposits Insurance Corporation. However, the Company has not experienced losses on these accounts and management believes that the Company is not exposed to significant risks on such accounts.
Property and Equipment	Property and Equipment Lab equipment, leasehold improvements and office equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset, generally three years.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value.
Accounting for Warrants	Accounting for Warrants The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging (“ASC 815”). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants as of the date of each offering and reassesses such classification at each financial reporting date. The Company determined that such instruments did not meet the criteria for liability classification.
Research and Development	Research and Development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations, consultants, the cost of acquiring and manufacturing research trial materials, and costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development
Contingencies	Contingencies The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.
Income Taxes	Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.
Loss Per Share	Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share excludes the potential impact of common stock options, unvested shares of restricted stock and outstanding common stock purchase warrants because their effect would be anti-dilutive. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at December 31, 2016 and 2015 are as follows: As of December 31, 2016 2015 Warrants to purchase common stock 3,271,875 1,850,000 Options to purchase common stock 4,530,000 3,870,000 Unvested restricted stock - 650,000 Total 7,801,875 6,370,000
Non-Controlling Interests	Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests.
Reclassfication	Reclassfication Certain prior period amounts have been reclassified to conform to current year presentation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”) . Under ASU 2016-09, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (“APIC”). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement and the APIC pools will be eliminated. In addition, ASU 2016-09 eliminates the requirement that excess tax benefits be realized before companies can recognize them. ASU 2016-09 also requires companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Furthermore, ASU 2016-09 will increase the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer’s statutory income tax withholding obligation. An employer with a statutory income tax withholding obligation will now be allowed to withhold shares with a fair value up to the amount of taxes owed using the maximum statutory tax rate in the employee’s applicable jurisdiction(s). ASU 2016-09 requires a company to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on the statement of cash flows. Under current GAAP, it was not specified how these cash flows should be classified. In addition, companies will now have to elect whether to account for forfeitures on share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. These aspects of ASU 2016-09 are effective for reporting periods beginning after December 15, 2016, with early adoption permitted provided that all of the guidance is adopted in the same period. The Company adopted the standard as of January 1, 2017 and adoption did not have a material impact on the Company’s consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments

Organization and Operations (Ta

Organization and Operations (Tables)	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Ownership Interest in the Subsidiary Company	Following the sale of CLC’s shares, the ownership is as follows: Stockholder Shares Percentage alpha-En Corporation 9,095,000 90.95 % Non-controlling interests 905,000 9.05 % Total: 10,000,000 100.00 %

Significant and Critical Acco18

Significant and Critical Accounting Policies and Practices (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at December 31, 2016 and 2015 are as follows: As of December 31, 2016 2015 Warrants to purchase common stock 3,271,875 1,850,000 Options to purchase common stock 4,530,000 3,870,000 Unvested restricted stock - 650,000 Total 7,801,875 6,370,000

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	The components of property and equipment as of December 31, 2016 and 2015, at cost are (dollars in thousands): ($ in thousands) Useful Life (Years) December 31, 2016 December 31, 2015 Lab equipment 3 173 2 Office furniture and equipment 3 12 - Leasehold improvement 368 - Gross property and equipment 553 2 Less: Accumulated depreciation (12 ) - Property and equipment, net $ 541 $ 2

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Adjustment to Outstanding Shares and Options Equity	The following table provides a comparison between the previously filed numbers and the numbers after the correction as of December, 31(in thousands, except share): Previous Filings After Correction of Error 2015 2014 2015 2014 Total shares outstanding 28,649,497 26,699,497 32,235,525 30,285,525 Common stock $ 286 $ 267 $ 322 $ 303 Additional paid-in capital $ 10,741 $ 8,130 $ 10,705 $ 8,094
Schedule of Adjustment to Outstanding Shares and Options Operation	The following table provides a comparison between the previously filed numbers and the numbers after the correction for the years ended December, 31: Previous Filings After Correction of Error 2015 2014 2015 2014 Net loss $ 1,792,000 $ 47,000 $ 1,792,000 $ 47,000 Net loss per share $ (0.07 ) $ (0.00 ) $ (0.06 ) $ (0.00 ) Weighted-average shares 27,263,059 26,394,554 30,849,087 29,980,582
Schedule of Fair Value of Assumptions	The fair value of options granted in 2016 and 2015 was estimated using the following weighted-average assumptions: As of December 31, 2016 2015 Exercise price $ 1.03 $ 0.28 Expected stock price volatility 79 % 78 % Risk-free rate of interest 1.37 % 1.28 % Term (years) 3.7 3.8
Schedule of Nonvested Restricted Stock	A summary of the restricted stock award activity for the year ended December 31, 2016 is as follows: Number of Units Weighted Average Grant Date Fair Value Nonvested at December 31, 2015 650,000 $ 0.40 Vested (650,000 ) $ 0.40 Nonvested at December 31, 2016 - $ - A summary of the restricted stock award activity for the year ended December 31, 2015 is as follows: Number of Units Weighted Average Grant Day Fair Value Nonvested at December 31, 2014 - $ - Granted 1,000,000 $ 0.40 Vested (350,000 ) $ 0.40 Nonvested at December 31, 2015 650,000 $ 0.40
Schedule of Warrants Outstanding	A summary of the status of the Company’s outstanding warrants as of December 31, 2016 and changes during the year then ended is presented below: Number of Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 1,850,000 $ 0.31 $ 1,249,000 4.3 Issued 1,643,750 1.82 250,000 2.3 Exercised (221,875 ) 0.97 73,000 4.2 Outstanding as of December 31, 2016 3,271,875 $ 1.02 $ 2,000,000 3.9 Warrants exercisable as of December 31, 2016 3,271,875 $ 1.02 $ 2,000,000 3.9
Schedule of Stock-based Compensation Expense	Stock-based compensation expense for the year ended December 31, 2016 and 2015 was comprised of the following (in thousands): For the Years Ended December 31, 2016 2015 Employee restricted stock awards $ 136 $ 264 Employee stock option awards 201 30 Non-employee option awards 1,245 687 Total compensation expense $ 1,582 $ 981
Employee Stock Option [Member]
Schedule of Stock Options, Activity	A summary of option activity under the Company’s employee stock option plan for year ended December 31, 2016 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 1,050,000 $ 0.27 $ 757,000 5.1 Employee options granted 525,000 0.97 182,000 5.7 Outstanding as of December 31, 2016 1,575,000 $ 0.50 $ 1,264,000 4.7 Options vested and expected to vest as of December 31, 2016 1,575,000 $ 0.50 $ 1,264,000 4.7 Options vested and exercisable as of December 31, 2016 687,500 $ 0.36 $ 647,000 3.8
Non Employee Stock Option [Member]
Schedule of Stock Options, Activity	A summary of the activity of options that the Company granted to non-employees for the year ended December 31, 2016 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 (as reported) 2,670,000 $ 0.20 $ 2,118,000 4.0 Adjustment to stock options 150,000 0.10 134,000 2.1 Outstanding as of December 31, 2015 (as adjusted) 2,820,000 $ 0.19 $ 2,252,000 3.9 Non-employee options granted 235,000 $ 1.15 $ 46,000 4.9 Non-employee options exercised (100,000 ) 0.11 119,000 - Outstanding as of December 31, 2016 2,955,000 $ 0.27 $ 3,053,000 3.2 Options vested and expected to vest as of December 31, 2016 2,955,000 $ 0.27 $ 3,053,000 3.2 Options vested and exercisable as of December 31, 2016 1,667,500 $ 0.30 $ 1,660,700 3.3

Contingencies and Commitments (

Contingencies and Commitments (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Contractual Minimal Lease Payments	Contractual minimal lease payments are as follows (in thousands): 2017 $ 121 2018 210 2019 213 2020 216 2021 220 Thereafter 543 Total $ 1,523

Deferred Tax Assets and Incom22

Deferred Tax Assets and Income Tax Provision (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	As of December 31, 2016 2015 Deferred tax assets: Net-operating loss carryforward $ 1,196 $ 342 Stock based compensation 1,043 431 Total Deferred Tax Assets 2,239 773 Valuation allowance (2,239 ) (773 ) Deferred Tax Asset, Net of Allowance $ - $ -
Schedule of Income Tax Expense (Benefit)	For the year ended 2016 2015 Federal Current $ - $ - Deferred 1,251 643 State Current - - Deferred 215 110 Change in Valuation Allowance (1,466 ) (753 ) Income Tax Provision (Benefit) $ - -
Schedule of Effective Income Tax Rate Reconciliation	For the years ended December 31, 2016 2015 Statutory Federal Income Tax Rate (34.0 )% (34.0 )% State Taxes, Net of Federal Tax Benefit (5.8 )% (5.8 )% Change in Valuation Allowance 39.8 % 39.8 % Income Taxes Provision (Benefit) 0.0 % 0.0 %

Organization and Operations (De

Organization and Operations (Details Narrative) $ in Thousands	Dec. 31, 2014USD ($)
Clean Lithium Corporation [Member]
Franchisor Disclosure [Line Items]
Capital	$ 100

Organization and Operations - S

Organization and Operations - Schedule of Ownership Interest in the Subsidiary Company (Details) - shares	Dec. 31, 2016	Dec. 31, 2015
Shares, outstanding		32,235,525
Equity method investment, ownership percentage	100.00%
Clean Lithium Corporation [Member]
Shares, outstanding	10,000,000
Equity method investment, ownership percentage	100.00%
Alpha-En Corporation [Member] | Clean Lithium Corporation [Member]
Shares, outstanding	9,095,000
Equity method investment, ownership percentage	90.95%
Noncontrolling Interest [Member] | Clean Lithium Corporation [Member]
Shares, outstanding	905,000
Equity method investment, ownership percentage	9.05%

Going Concern and Liquidity (De

Going Concern and Liquidity (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Retained earnings (\accumulated deficit	$ 13,749	$ 10,169
Net loss	4,074	1,792
Net cash provided by operating activities, continuing operations	$ 1,473	$ 895

Significant and Critical Acco26

Significant and Critical Accounting Policies and Practices (Details Narrative)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Ownership percentage	100.00%
Office equipment, useful life	3 years

Significant and Critical Acco27

Significant and Critical Accounting Policies and Practices - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	7,801,875	6,370,000
Unvested Restricted Stock [Member]
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		650,000
Stock Option [Member]
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	4,530,000	3,870,000
Warrant [Member]
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	3,271,875	1,850,000

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 12	$ 0

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Gross property and equipment	$ 553	$ 2
Less: Accumulated depreciation	(12)
Property and equipment, net	$ 541	2
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Gross property and equipment	$ 173	2
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Gross property and equipment	$ 12
Leasehold Improvement [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 368

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Dec. 06, 2016	Nov. 02, 2016	Jun. 03, 2016	Dec. 31, 2016	Dec. 31, 2015	Nov. 01, 2016
Related Party Transaction [Line Items]
Proceeds from related party debt				$ 86	$ 11
Repayments of related party debt				70	87
Advances from related parties outstanding amount				$ 78	$ 62
Sale of common stock				3,600,000
Warrants exercise price				$ 0.97
Number of shares cancelled	210,000
Common stock exchanged to option exercise	210,000
Exercise price per share	$ 1.08
Stock conversions term	5 years
Payments for secretarial services				$ 16,000
Jim Kilman [Member] | Private Placement [Member]
Related Party Transaction [Line Items]
Sale of common stock		100,000	100,000
Warrant purchase of common stock, shares			250,000			250,000
Sale of common stock and warrants value		$ 100	$ 250
Warrants term		5 years	5 years
Warrants exercise price			$ 3.79			$ 1.16
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments related to tax withholding for share-based compensation				$ 198

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jan. 15, 2016	Dec. 18, 2015	Aug. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Number of common shares				3,600,000
Number of stock option				75,000
Number of common stock issued for service, value				$ (75)
Number of warrant exercised for cash consideration				221,875
Exercise price of warrant				$ 0.97
Number of warrant exercised for cash consideration, value				$ 215
Fair value of warrants				$ 378
Class of warrant or right, issued				3,271,875
Class of warrant or right, outstanding				3,271,875
Fair value of stock option granted				$ 305	$ 135
Stock based compensation expense relating to unvested				$ 225
Amortized period				3 years 9 months 18 days
Expected stock price volatility				79.00%	78.00%
Risk-free rate of interest				1.37%	1.28%
Term (years)				3 years 8 months 12 days	3 years 9 months 18 days
Restricted Stock [Member]
Number of warrants granted					1,000,000
2016 Equity Plan [Member]
Fair value of stock option granted				$ 431
Dividend yield				0.00%
Expected dividends				0.00%
Mr. Fludder [Member] | Restricted Stock [Member]
Number of common shares	650,000	350,000
Expenses related to restricted stock				$ 136	$ 264
November 2016 [Member]
Number of additional shares of common stock issued under arrangement				100,000
Clean Lithium Corporation [Member] | Consultant [Member]
Exercise price per shares				$ 1
Number of common stock issued for service				75,000
Number of common stock issued for service, value				$ 75
Private Placement [Member] | Investor [Member]
Number of common shares				1,500,000	1,600,000
Warrant purchase of common stock, shares				1,400,000	1,700,000
Warrant to purchase of common stock				$ 1,400	$ 1,600
Warrant term				5 years
Warrant, weighted average exercise price				$ 1.68
Exercise price per shares				$ 2.50
Private Placement [Member] | Investor [Member] | Clean Lithium Corporation [Member]
Number of common shares					680,000
Common Stock [Member]
Number of common shares				3,600,000
Additional Shares [Member] | Private Placement [Member] | Investor [Member]
Number of common shares				100,000
Non-Employee [Member]
Number of stock option				150,000
Price Protection [Member] | Private Placement [Member] | Investor [Member]
Warrant purchase of common stock, shares				100,000
Additional Warrants [Member] | Investor [Member]
Warrant term			5 years
Exercise price of warrant			$ 2.70
Number of warrants granted			221,875
Warrant [Member]
Dividend yield				0.00%
Expected stock price volatility				78.49%
Risk-free rate of interest				1.14%
Term (years)				5 years
Expected dividends				0.00%

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Adjustment to Outstanding Shares and Options Equity (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Total shares outstanding		32,235,525
Common stock	$ 333	$ 322
Additional paid-in capital	$ 13,987	$ 10,705
Previous Filings [Member]
Total shares outstanding		28,649,497	26,699,497
Common stock		$ 286	$ 267
Additional paid-in capital		$ 10,741	$ 8,130
After Correction of Error [Member]
Total shares outstanding		32,235,525	30,285,525
Common stock		$ 322	$ 303
Additional paid-in capital		$ 10,705	$ 8,094

Stockholders' Equity - Schedu33

Stockholders' Equity - Schedule of Adjustment to Outstanding Shares and Options Operation (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net loss	$ (4,074)	$ (1,792)
Net loss per share	$ (0.12)	$ (0.06)
Weighted-average shares	33,347,318	30,849,087
Previous Filings [Member]
Net loss		$ 1,792	$ 47
Net loss per share		$ (0.07)	$ 0
Weighted-average shares		27,263,059	26,394,554
After Correction of Error [Member]
Net loss		$ 1,792	$ 47
Net loss per share		$ (0.06)	$ 0
Weighted-average shares		30,849,087	29,980,582

Stockholders' Equity - Schedu34

Stockholders' Equity - Schedule of Fair Value of Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Equity [Abstract]
Exercise price	$ 1.03	$ 0.28
Expected stock price volatility	79.00%	78.00%
Risk-free rate of interest	1.37%	1.28%
Term (years)	3 years 8 months 12 days	3 years 9 months 18 days

Stockholders' Equity - Schedu35

Stockholders' Equity - Schedule of Stock Options, Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 0.28
Weighted Average Exercise Price, Outstanding, Ending Balance	$ 1.03	$ 0.28
Employee Stock Option [Member]
Number of Shares, Outstanding, Beginning Balance	1,050,000
Number of Shares, Options granted	525,000
Number of Shares, Outstanding, Ending Balance	1,575,000	1,050,000
Number of Shares, Options vested and expected to vest	1,575,000
Number of Shares, Options vested and exercisable	687,500
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 0.27
Weighted Average Exercise Price, Options granted	0.97
Weighted Average Exercise Price, Outstanding, Ending Balance	0.50	$ 0.27
Weighted Average Exercise Price, Options vested and expected to vest	0.50
Weighted Average Exercise Price, Options vested and exercisable	$ 0.36
Intrinsic Value, Outstanding, Beginning Balance	$ 757,000
Intrinsic Value, Options granted	182,000
Intrinsic Value, Outstanding, Ending Balance	1,264,000	$ 757,000
Intrinsic Value, Options vested and expected to vest	1,264,000
Intrinsic Value, Options vested and exercisable	$ 647,000
Weighted Average Remaining Contractual Life (in years), Outstanding, Beginning Balance	5 years 1 month 6 days
Weighted Average Remaining Contractual Life (in years), Options granted	5 years 8 months 12 days
Weighted Average Remaining Contractual Life (in years), Outstanding, Ending Balance	4 years 8 months 12 days
Weighted Average Remaining Contractual Life (in years), Options vested and expected to vest	4 years 8 months 12 days
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable	3 years 9 months 18 days
Non Employee Stock Option [Member]
Number of Shares, Outstanding, Beginning Balance	2,820,000	2,670,000
Number of Shares, Adjustment to stock options		150,000
Number of Shares, Options granted	235,000
Number of Shares, Option Exercised	(100,000)
Number of Shares, Outstanding, Ending Balance	2,955,000	2,820,000
Number of Shares, Options vested and expected to vest	2,955,000
Number of Shares, Options vested and exercisable	1,667,500
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 0.19	$ 0.20
Weighted Average Exercise Price, Adjustment to stock options		0.10
Weighted Average Exercise Price, Options granted	1.15
Weighted Average Exercise Price, Options Exercised	0.11
Weighted Average Exercise Price, Outstanding, Ending Balance	0.27	$ 0.19
Weighted Average Exercise Price, Options vested and expected to vest	0.27
Weighted Average Exercise Price, Options vested and exercisable	$ 0.30
Intrinsic Value, Outstanding, Beginning Balance	$ 2,252,000	$ 2,118,000
Intrinsic Value, Adjustment to stock options		134,000
Intrinsic Value, Options granted	46,000
Intrinsic Value, Options exercised	119,000
Intrinsic Value, Outstanding, Ending Balance	3,053,000	$ 2,252,000
Intrinsic Value, Options vested and expected to vest	3,053,000
Intrinsic Value, Options vested and exercisable	$ 1,660,700
Weighted Average Remaining Contractual Life (in years), Outstanding, Beginning Balance	3 years 10 months 24 days	4 years
Weighted Average Remaining Contractual Life (in years), Options granted	4 years 10 months 24 days
Weighted Average Remaining Contractual Life (in years), Adjustment to stock options		2 years 1 month 6 days
Weighted Average Remaining Contractual Life (in years), Outstanding, Ending Balance	3 years 2 months 12 days	3 years 10 months 24 days
Weighted Average Remaining Contractual Life (in years), Options vested and expected to vest	3 years 2 months 12 days
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable	3 years 3 months 18 days

Stockholders' Equity - Schedu36

Stockholders' Equity - Schedule of Nonvested Restricted Stock (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Nonvested Restricted Stock [Member]
Number of Units, Nonvested, Beginning Balance	650,000
Number of Units, Granted
Number of Units, Vested	(650,000)
Number of Units, Nonvested, Ending Balance		650,000
Weighted Average Grant Day Fair Value, Nonvested, Beginning Balance	$ 0.40
Weighted Average Grant Day Fair Value, Vested	0.40
Weighted Average Grant Day Fair Value, Nonvested, Ending Balance		$ 0.40
Restricted Stock [Member]
Number of Units, Nonvested, Beginning Balance
Number of Units, Granted		1,000,000
Number of Units, Vested		(350,000)
Weighted Average Grant Day Fair Value, Nonvested, Beginning Balance
Weighted Average Grant Day Fair Value, Granted		0.40
Weighted Average Grant Day Fair Value, Vested		$ 0.40

Stockholders' Equity - Schedu37

Stockholders' Equity - Schedule of Warrants Outstanding (Details) - Warrant [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Number of Warrant, Beginning | shares	1,850,000
Number of Warrant, Issued | shares	1,643,750
Number of Warrant, Exercised | shares	(221,875)
Number of Warrant, Ending | shares	3,271,875
Number of Warrants, Warrants exercisable | shares	3,271,875
Weighted Average Exercise Price, Outstanding, Beginning Balance | $ / shares	$ 0.31
Weighted Average Exercise Price, Issued | $ / shares	1.82
Weighted Average Exercise Price, Exercised | $ / shares	0.97
Weighted Average Exercise Price, Outstanding, Ending Balance | $ / shares	1.02
Weighted Average Exercise Price, Warrants exercisable | $ / shares	$ 1.02
Intrinsic Value, Outstanding, Beginning Balance | $	$ 1,249
Intrinsic Value, Issued | $	350
Intrinsic Value, Exercised | $	(173)
Intrinsic Value, Outstanding, Ending Balance | $	2,000
Intrinsic Value, Warrants exercisable | $	$ 2,000
Weighted Average Remaining Contractual Life (in years), Outstanding, Beginning Balance	4 years 3 months 18 days
Weighted Average Remaining Contractual Life (in years), Issued	4 years 10 months 24 days
Weighted Average Remaining Contractual Life (in years), Exercised	4 years 4 months 24 days
Weighted Average Remaining Contractual Life (in years), Outstanding, Ending Balance	3 years 10 months 24 days
Weighted Average Remaining Contractual Life (in years), Warrants exercisable	3 years 10 months 24 days

Stockholders' Equity - Schedu38

Stockholders' Equity - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation	$ 1,582	$ 981
Employee Restricted Stock Awards [Member]
Share-based Compensation	136	264
Employee Stock Option [Member]
Share-based Compensation	201	30
Non Employee Stock Option [Member]
Share-based Compensation	$ 1,245	$ 687

Contingencies and Commitments39

Contingencies and Commitments (Details Narrative)	12 Months Ended
	Dec. 31, 2016USD ($)ft²
Area of lease | ft²	8,000
Line of credit facility, maximum borrowing capacity	$ 150,000
Description of commitments	Pursuant to the amendment and release, the third party retained two million of the three million total shares from the original license and forfeited the remaining one million shares. The two million shares retained by the third party are subject to customary transfer restrictions for restricted shares.
Operating lease rent	$ 208,000
Percentage of increase in lease rent	1.50%
Jerome I. Feldman [Member]
Operating lease rent	$ 5,000
Lease expiration date	Apr. 30, 2018

Contingencies and Commitments -

Contingencies and Commitments - Schedule of Contractual Minimal Lease Payments (Details) $ in Thousands	Dec. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,017	$ 121
2,018	210
2,019	213
2,020	216
2,021	220
Thereafter	543
Total	$ 1,523

Deferred Tax Assets and Incom41

Deferred Tax Assets and Income Tax Provision (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 3,100
Operating loss carry forwards, expiration term	expires beginning in 2036
Valuation allowance, deferred tax asset, increase amount	$ 1,466	$ 753

Deferred Tax Assets and Incom42

Deferred Tax Assets and Income Tax Provision - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Net-operating loss carryforward	$ 1,196	$ 342
Stock based compensation	1,043	431
Total Deferred Tax Assets	2,239	773
Valuation allowance	(2,239)	(773)
Net Deferred Tax Asset

Deferred Tax Assets and Incom43

Deferred Tax Assets and Income Tax Provision - Schedule of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Federal Current
Federal Deferred	1,251	643
State Current
State Deferred	215	110
Change in Valuation Allowance	(1,466)	(753)
Income Tax Provision (Benefit)

Deferred Tax Assets and Incom44

Deferred Tax Assets and Income Tax Provision - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Statutory Federal Income Tax Rate	(34.00%)	(34.00%)
State Taxes, Net of Federal Tax Benefit	(5.80%)	(5.80%)
Change in Valuation Allowance	39.80%	39.80%
Income Taxes Provision (Benefit)	0.00%	0.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Feb. 23, 2017	Dec. 31, 2016	Mar. 29, 2017	Dec. 31, 2015
Number of stock options vested		75,000
Ownership percentage		100.00%
Common stock, par value		$ 0.01		$ 0.01
Subsequent Event [Member] | Board of Directors [Member]
Ownership percentage			75.00%
Number of capital stock authorized			60,000,000
Subsequent Event [Member] | Board of Directors [Member] | Preferred Stock [Member]
Number of capital stock authorized			2,000,000
Common stock, par value			$ 0.01
Subsequent Event [Member] | Board of Directors [Member] | Common Stock [Member]
Number of capital stock authorized			57,000,000
Common stock, par value			$ 0.01
Subsequent Event [Member] | Board of Directors [Member] | Class B Common Stock [Member]
Number of capital stock authorized			1,000,000
Common stock, par value			$ 0.01
Subsequent Event [Member] | Nathan Wasserman [Member] | Chief Financial Officer [Member]
Number of stock options granted	500,000
Stock options exercise price	$ 1.50
Number of stock options vested	150,000
Salary	$ 5,000
Subsequent Event [Member] | Nathan Wasserman [Member] | Chief Financial Officer [Member] | Second Year [Member]
Number of stock options vested	150,000
Subsequent Event [Member] | Nathan Wasserman [Member] | Chief Financial Officer [Member] | Third Year [Member]
Number of stock options vested	200,000